Download or read book Current Hypotheses and Research Milestones in Alzheimer s Disease written by Ricardo B. Maccioni and published by Springer Science & Business Media. This book was released on 2009-02-27 with total page 242 pages. Available in PDF, EPUB and Kindle. Book excerpt: Almost four decades of innovative and intensive research on Alzheimer’s disease (AD) have brought major advances in our understanding of its pathogenesis, improved tools for diagnosis, and strategies for its treatment. This research has helped build a solid foundation of knowledge in the neurosciences and biological basis of AD and AD-related neurological disorders. Scientific background and insightful hypotheses are of major relevance in order to approach to an effective therapy for this devastating disease. Current Hypotheses and Research Milestones in Alzheimer's Disease contains 20 seminal chapters by authors with varying views on the neuroanatomical, neuropathological, neuropsychological, neurological, and molecular aspects of AD. These chapters grew out of “Current Hypothesis on Alzheimer’s Disease”, held in Viña del Mar, Chile, in November of 2007. Participants included the world’s leading Alzheimer’s researchers, whose work has illuminated AD investigations during the past few decades. Students, academics and medical professionals will find this text an invaluable addition to the study of this important subject.
Download or read book Managing Discovery in the Life Sciences written by Philip A. Rea and published by Cambridge University Press. This book was released on 2018-02-01 with total page 558 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this book, distinguished scholars Philip A. Rea, Mark V. Pauly, and Lawton R. Burns explore the science and management behind marketable biomedical innovations. They look at how the science actually played out through the interplay of personalities, the cultures within and between academic and corporate entities, and the significance of serendipity not as a mysterious phenomenon but one intrinsic to the successes and failures of the experimental approach. With newly aggregated data and case studies, they consider the fundamental economic underpinnings of investor-driven discovery management, not as an obstacle or deficiency as its critics would contend or as something beyond reproach as some of its proponents might claim, but as the only means by which scientists and managers can navigate the unknowable to discover new products and decide how to sell them so as to maximize the likelihood of establishing a sustainable pipeline for still more marketable biomedical innovations.
Download or read book The End of Alzheimer s written by Thomas J. Lewis and published by Academic Press. This book was released on 2017-05-12 with total page 484 pages. Available in PDF, EPUB and Kindle. Book excerpt: The End of Alzheimer's: The Brain and Beyond, Second Edition is the first comprehensive overview on the molecular basis of Alzheimer's outside of the brain, merging the most recent findings within the field into a single book. It aims to educate the reader on the many overlooked aspects of Alzheimer's disease that occur outside the brain. This book uniquely provides step-by-step, peer-reviewed evidence that the current research model may be misguided and that a new and emerging model is more accurate. It carefully outlines the molecular research in Alzheimer's outside the brain and argues that a more thorough, whole-body diagnosis will provide better answers about its causes and lead to new treatments. It is beneficial to researchers who need to be apprised of the emerging science on the causes of Alzheimer's, and will hopefully redirect many into new avenues of cellular research and discovery. - Comprehensive literature-based summary of the current state of molecular Alzheimer's disease research - Details the shortcomings of the prevailing model and therapeutics in development - Reviews blood-based biomarkers for Alzheimer's and their link to amyloid- and Tau-independent causes outside the brain - Describes the tissues outside the brain impacted by Alzheimer's and the underlying molecular causes - Explains the whole-body risks associated with Alzheimer's, along with concomitant measures to slow or prevent the disease - Provides a protocol to properly research, evaluate, measure, diagnose, and potentially treat Alzheimer's patients
Download or read book Cognitive Neuroscience written by Marie T. Banich and published by Cambridge University Press. This book was released on 2023-09-30 with total page 671 pages. Available in PDF, EPUB and Kindle. Book excerpt: The fifth edition of this comprehensive text explains the key issues, concepts and clinical applications of cognitive neuroscience.
Download or read book Neuroscience written by Carlos M. Contreras and published by BoD – Books on Demand. This book was released on 2012-03-16 with total page 444 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Neuronal Doctrine recently reached its 100th year and together with the development of psychopharmacology by the middle of 20th century promoted spectacular developments in the knowledge of the biological bases of behavior. The overwhelming amount of data accumulated, forced the division of neuroscience into several subdisciplines, but this division needs to dissolve in the 21st century and focus on specific processes that involve diverse methodological and theoretical approaches. The chapters contained in this book illustrate that neuroscience converges in the search for sound answers to several questions, including the pathways followed by cells, how individuals communicate with each other, inflammation, learning and memory, the development of drug dependence, and approaches to explaining the processes that underlie two highly incapacitating chronic degenerative illnesses.
Download or read book Update on Dementia written by Davide Moretti and published by BoD – Books on Demand. This book was released on 2016-09-28 with total page 560 pages. Available in PDF, EPUB and Kindle. Book excerpt: The dementia challenge is the largest health effort of the times we live in. The whole society has to move to a realization of the significance of prioritization to make an attempt in the direction of mental health promotion and dementia risk reduction. New priorities for research are needed to go far beyond the usual goal of constructing a disease course-modifying medication. Moreover, a full empowerment and engagement of men and women living with dementia and their caregivers, overcoming stigma and discrimination should be promoted. The common efforts and the final aim will have to be the progress of a ''dementia-constructive'' world, where people with dementia can take advantage of equal opportunities.
Download or read book Non fibrillar Amyloidogenic Protein Assemblies Common Cytotoxins Underlying Degenerative Diseases written by Farid Rahimi and published by Springer Science & Business Media. This book was released on 2012-01-11 with total page 568 pages. Available in PDF, EPUB and Kindle. Book excerpt: Amyloid-forming proteins are implicated in over 30 human diseases. The proteins involved in each disease have unrelated sequences and dissimilar native structures, but they all undergo conformational alterations to form fibrillar polymers. The fibrillar assemblies accumulate progressively into disease-specific lesions in vivo. Substantial evidence suggests these lesions are the end state of aberrant protein folding whereas the actual disease-causing culprits likely are soluble, non-fibrillar assemblies preceding the aggregates. The non-fibrillar protein assemblies range from small, low-order oligomers to spherical, annular, and protofibrillar species. Oligomeric species are believed to mediate various pathogenic mechanisms that lead to cellular dysfunction, cytotoxicity, and cell loss, eventuating in disease-specific degeneration and systemic morbidity. The particular pathologies thus are determined by the afflicted cell types, organs, systems, and the proteins involved. Evidence suggests that the oligomeric species may share structural features and possibly common mechanisms of action. In many cases, the structure–function interrelationships amongst the various protein assemblies described in vitro are still elusive. Deciphering these intricate structure–function correlations will help understanding a complex array of pathogenic mechanisms, some of which may be common across different diseases albeit affecting different cell types and systems.
Download or read book Herpesviridae written by Joseph Ongrádi and published by BoD – Books on Demand. This book was released on 2016-09-07 with total page 273 pages. Available in PDF, EPUB and Kindle. Book excerpt: Herpesviruses are unique among viruses as they encode for a complex self-regulatory system, aggressively invade and persist in the host, evade immune defense, alter all regulatory mechanisms of the macroorganism and modify the replication of heterologous viruses. Environmental factors influence these unconventional relationships. Consequently, a single herpesvirus species can be attributed to a wide range of diseases as etiological agents or cofactors. This book is intended to give an overview on selected clinical hot topics: herpes simplex virus encephalitis, persistent infection in the gingiva, thymidine kinase gene expression causing male infertility, and pharmaceutical reactivation of Epstein-Barr virus for oncolysis. Immune evasion mechanisms and new ways to formulate vaccines are exhaustively reviewed. Finally, a surprise: bovine herpesviruses could serve as models to study the pathomechanism of herpesviruses.
Download or read book Apolipoprotein E and Alzheimer s Disease written by A.D. Roses and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 208 pages. Available in PDF, EPUB and Kindle. Book excerpt: There is now considerable genetic evidence that the type 4 allele of the apolipoprotein E gene is a major susceptibility factor associated with late-onset Alzheimer's disease, the common form of the disease defined as starting after sixty years of age. The role of apolipoprotein E in normal brain metabolism and in the pathogenesis of Alzheimer's disease are new and exciting avenues of research. This book, written by the most outstanding scientists in this new filed, is the first presentation of results concerning the implications of apolipoprotein E on the genetics, cell biology, neuropathology, biochemistry, and therapeutic management of Alzheimer's disease.
Download or read book Alzheimer s In America written by Maria Shriver and published by Free Press. This book was released on 2011-04-12 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Shriver Report: A Woman’s Nation Takes on Alzheimer’s will be the first comprehensive multi-disciplinary look at these questions at this transformational moment. The Report will digest the current trends in thinking about Alzheimer’s, examine cutting-edge medical research, look at societal impacts, and include a groundbreaking and comprehensive national poll. It will feature original photography and personal essays by men and women – some from the public arena with names you know, some from everyday America – sharing their personal struggles with the disease as patients, caregivers and family members.
Download or read book Mechanisms of Innate Neuroprotection written by Giuseppe Pignataro and published by Frontiers Media SA. This book was released on 2016-07-27 with total page 140 pages. Available in PDF, EPUB and Kindle. Book excerpt: As clinical trials of pharmacological neuroprotective strategies in stroke have been disappointing, attention has turned to the brain's own endogenous strategies for neuroprotection. Two endogenous mechanisms have been recently characterized, ischemic preconditioning and ischemic postconditioning. In the present topic newly characterized mechanisms involved in preconditioning- and postconditioning- neuroprotection will be discussed. The understanding of the mechanisms involved in the neuroprotective pathways induced by preconditioning and postconditioning will be clinically relevant for identifying new druggable target for neurodegenerative disorder therapy. Furthermore, the importance of these neuroprotective strategies resides in that it might be easily translatable into clinical practice. Therefore, the data presented here will highlight the capacity of ischemic preconditioning and postconditioning to be of benefit to humans.
Download or read book Sharing Clinical Trial Data written by Institute of Medicine and published by National Academies Press. This book was released on 2015-04-20 with total page 236 pages. Available in PDF, EPUB and Kindle. Book excerpt: Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research-from funders, to researchers, to journals, to physicians, and ultimately, to patients.
Download or read book The British National Bibliography written by Arthur James Wells and published by . This book was released on 2009 with total page 1922 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Molecular and Cellular Mechanisms of Neuronal Plasticity in Normal Aging and Alzheimer s Disease written by Paul D. Coleman and published by . This book was released on 1990 with total page 364 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Improving and Accelerating Therapeutic Development for Nervous System Disorders written by Institute of Medicine and published by National Academies Press. This book was released on 2014-02-06 with total page 107 pages. Available in PDF, EPUB and Kindle. Book excerpt: Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
Download or read book Alzheimer s Disease Drug Development written by Jeffrey Cummings and published by Cambridge University Press. This book was released on 2022-03-31 with total page 575 pages. Available in PDF, EPUB and Kindle. Book excerpt: Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.
Download or read book Rare Diseases and Orphan Products written by Institute of Medicine and published by National Academies Press. This book was released on 2011-04-03 with total page 442 pages. Available in PDF, EPUB and Kindle. Book excerpt: Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
